MHRA and EMA Divergence in Clinical Trial Oversight

Published on 25/12/2025

Divergence Between MHRA and EMA in Clinical Trial Oversight

Following Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) assumed full authority over the regulation of clinical trials in the United Kingdom (UK), while the European Medicines Agency (EMA) retained oversight within the European Union (EU). While both agencies share a commitment to Good Clinical Practice (GCP) and international harmonisation, important divergences have emerged. These differences affect clinical trial authorisations, pharmacovigilance obligations, transparency requirements, and inspection practices. Sponsors operating global or multi-regional trials must understand these divergences to remain compliant and to ensure trial data generated in the UK remains globally acceptable.

This article analyses areas where MHRA and EMA oversight aligns, and where post-Brexit divergence has created new obligations for sponsors, investigators, and CROs conducting trials in the UK and EU.

Table of Contents

Background and Regulatory Framework

Pre-Brexit Alignment

Before Brexit, the UK followed EU Clinical Trials Directive 2001/20/EC and prepared for the EU Clinical Trials Regulation (CTR) 536/2014. Approvals, safety reporting, and transparency obligations were harmonised under EMA-led structures.

Post-Brexit Separation

From January 2021, UK clinical trial regulation became independent. While MHRA retained alignment with ICH GCP and WHO guidance, the UK introduced standalone guidance and adapted approval

pathways for Clinical Trial Authorisations (CTAs).

Global Harmonisation

Both EMA and MHRA continue to align with ICH guidelines, but divergence in implementation details, systems (CTIS vs UK portals), and timelines has created complexity for sponsors managing multinational trials.

Key Areas of Divergence

1. Clinical Trial Authorisation (CTA) Process

The EU requires sponsors to submit applications through the Clinical Trials Information System (CTIS), ensuring single dossier review across Member States. In contrast, the UK requires direct submission to MHRA via its own systems, creating duplication for multinational sponsors.

2. Transparency and Registries

EMA mandates public disclosure of trial documents via CTIS, including protocols and lay summaries. The UK relies on ISRCTN or ClinicalTrials.gov, with HRA enforcing results disclosure within 12 months. This leads to fragmented transparency obligations.

3. Safety Reporting Obligations

Both EMA and MHRA require prompt reporting of SUSARs and DSURs. However, the EU uses EudraVigilance for centralised submissions, while the UK operates a separate MHRA safety reporting portal.

4. Inspections and GCP Enforcement

EMA coordinates GCP inspections across Member States, while MHRA conducts independent inspections in the UK. Reports show that MHRA has focused heavily on data integrity and TMF completeness, while EMA emphasises harmonisation and systemic oversight.

5. Data Protection and GDPR

EU Member States follow GDPR, whereas the UK applies the Data Protection Act 2018 and the Data Protection and Digital Information (DPDI) Bill. While principles remain similar, operational differences can complicate multinational trial data handling.

6. Decentralised and Hybrid Trials

EMA is developing reflection papers on decentralised elements, while MHRA has been quicker to adopt DCT frameworks, allowing home delivery of IMPs and eConsent validation. This divergence may make the UK a more flexible jurisdiction for early adoption of digital models.

Best Practices for Sponsors Managing Divergence

Plan dual submissions to CTIS (EU) and MHRA portals (UK).
Maintain separate pharmacovigilance reporting workflows for MHRA and EMA.
Develop harmonised SOPs to address both GDPR and UK data protection requirements.
Monitor evolving MHRA guidance, especially around DCTs and inspection priorities.
Conduct regular TMF audits to align with both EMA and MHRA expectations.

Scientific and Regulatory Evidence

EU Clinical Trials Regulation 536/2014
Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
MHRA Guidance on Clinical Trials Post-Brexit
EMA Reflection Paper on Decentralised Trials
ICH E6(R2) and draft E6(R3) GCP Guidelines

Special Considerations

Oncology Trials: Divergent reporting rules may delay multinational oncology programmes unless harmonised SOPs are in place.
Rare Diseases: UK flexibility for decentralised models may provide better access for geographically dispersed patients.
Pediatrics: Divergence in REC expectations requires dual adaptation of consent and assent materials.
Advanced Therapies: EMA and MHRA differ in inspection focus for ATMPs, with MHRA placing more weight on long-term follow-up documentation.

When Sponsors Should Seek Regulatory Advice

When planning multinational trials involving both UK and EU sites.
For rare disease or paediatric studies requiring harmonised submissions.
If trial designs involve decentralised elements subject to divergent regulatory acceptance.
For guidance on managing parallel PV and data protection requirements.
When preparing global submissions relying on both EMA and MHRA trial data.

FAQs

1. How do CTA processes differ between MHRA and EMA?

EMA uses CTIS for centralised submissions across EU Member States, while MHRA requires separate national submissions.

2. Are transparency obligations different in the UK and EU?

Yes. EMA mandates disclosure in CTIS, while the UK relies on ISRCTN and HRA timelines.

3. How does safety reporting differ?

EMA uses EudraVigilance, while MHRA has its own reporting systems, requiring sponsors to maintain dual workflows.

4. Does GDPR apply to UK trials?

The UK applies the Data Protection Act 2018 and DPDI Bill. GDPR no longer applies directly, but principles remain similar.

5. Which agency is more flexible with DCTs?

MHRA has shown greater flexibility, permitting home IMP delivery and eConsent validation sooner than EMA.

6. Do MHRA inspections differ from EMA inspections?

Yes. MHRA inspections focus strongly on TMF completeness and data integrity, while EMA coordinates systemic oversight across Member States.

7. What are the implications for global sponsors?

Global sponsors must manage dual systems, reporting obligations, and regulatory expectations to avoid delays and findings.

Conclusion

The divergence between MHRA and EMA in clinical trial oversight reflects the broader regulatory separation post-Brexit. While both agencies remain committed to GCP and international harmonisation, sponsors must adapt to differences in CTA processes, transparency obligations, pharmacovigilance systems, and inspection priorities. A proactive approach—engaging with regulators, aligning SOPs, and leveraging CRO expertise—will ensure trials in both regions remain compliant, efficient, and globally credible.